Triple negative breast cancer

• Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. Recruitment ended
  2024-513281-19-00 1 2024-11-25 "Nasopharyngeal Carcinoma"
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Recruitment ended
  2023-505928-59-00 5 2024-04-15 "Triple Negative or Hormone Receptor low/HER2-negative Breast"
• Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Recruitment ended
  2022-501561-51-00 4 2024-03-27 "Early and metastatic triple negative breast cancer"
• A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced … Recruitment ended
  2022-502381-25-01 1 2024-03-15 "Thymic Carcinoma"
• Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides … Recruitment ended
  2024-517580-23-00 1 2023-03-07 "Sarcoma"
• An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types. Recruitment ended
  2023-506868-14-00 9 2023-02-28 "Solid tumors in 4 tumor types: platinum resistant ovarian ca"
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Recruitment ended
  2023-505552-22-00 5 2023-02-24 "Stage I-III Triple-negative Breast Cancer with residual inva"
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Recruitment ended
  2023-509260-25-00 5 2022-07-12 "Locally Recurrent Inoperable or Metastatic Triple-negative B"
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants with HER2 Negative BRCAmut or Triple-Negative Breast Cancer with Mole … Recruitment ended
  2023-504454-35-00 5 2021-06-22 "Neoplasms, Breast"
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Recruitment ended
  2023-510390-33-00 5 2020-10-23 "HER2-negative breast cancer patients with high relapse risk "
• Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in t … Recruitment ended
  2023-508920-37-00 4 2020-05-20
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu … Recruitment ended
  2023-506184-34-00 5 2019-08-09 "Advanced Malignancies"
• A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Recruitment ended
  2024-511646-40-00 9 2019-07-11 "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC"
• A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Lo … Recruitment ended
  2024-511850-34-00 9 2019-01-02 "Previously untreated locally recurrent inoperable or metasta"
• A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Adv … Recruitment ended
  2024-516477-73-00 3 2018-03-07 "Bladder cancer and kidney cancer"
• A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combinatio … Recruitment ended
  2024-514205-60-00 4 2018-02-15 "Triple Negative Breast Cancer"
• A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants Ended
  2024-518696-65-00 3 2025-08-12 "(HR) -positive human epidermal growth factor receptor 2 (HER"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer Ended
  2022-502311-12-00 4 2024-04-05 "Patients with early-stage Triple Negative Breast Cancer"
• A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with … Ended
  2022-502457-34-00 4 2024-03-13 "Triple-Negative Breast Cancer (TNBC)"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 "Advanced or metastatic solid tumors"
• Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer Ended
  2022-500808-21-00 4 2023-02-01 "Metastatic triple negative breast cancer"
• A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Ended
  2023-504400-29-00 1 2022-09-15 "Advanced malignancies."
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended
  2024-511750-53-00 7 2022-09-08 "Unresectable Locally Advanced or Metastatic Cancer"

Showing 25–48 of 60 trials